Efficacy of Topical Cannabidiol for Eczema

NCT06994520 | Active Not Recruiting Phase 2

• 1 other identifier: HE671500
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life. Chronic pruritic skin conditions such as atopic dermatitis, nummular eczema, lichen simplex chronicus, and prurigo nodularis are frequently observed. The pathogenesis of these conditions remains incompletely understood, and effective long-term treatment options are limited. Current therapies include topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, and systemic immunosuppressants. However, these treatments are often associated with adverse effects, and the diseases tend to follow a chronic, relapsing course. Therefore, the investigators aim to investigate the efficacy and safety of topical cannabis extract in patients with chronic pruritic skin conditions.

Conditions

Chronic Pruritus; Eczema; Nummular Eczema; Atopic Dermatitis; Prurigo Nodularis

Outcome Measures

Primary Outcomes (6)

• Disease severity

  Disease severity was evaluated using a composite scoring system that assessed four clinical signs-erythema, induration, scaling, and scratching-along with the extent of area involvement. Each sign was graded on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The extent of area involvement was classified into six categories based on the percentage of body surface area affected: 1 = less than 10%; 2 = 10-\<30%; 3 = 30-\<50%; 4 = 50-\<70%; 5 = 70-\<90%; 6 = 90-100%. The overall severity score was obtained by summing the individual scores for erythema, induration, scaling, and dryness for each affected area and then multiplying this sum by the corresponding area involvement score. Higher total scores indicated greater disease severity.

  4 weeks

• Changing of erythema

  Erythema was graded on a scale from 0 to 3, with 0 indicating no redness, 1 mild, 2 moderate, and 3 severe redness.

  4 weeks

• Changing of induration

  Induration was graded on a scale from 0 to 3, with 0 indicating no induration, 1 mild, 2 moderate, and 3 severe skin thickening.

  4 weeks

• Changing of scaling

  Scaling (flaking of the skin) was graded on a scale from 0 to 3, with 0 indicating none, 1 mild, 2 moderate, and 3 severe.

  4 weeks

• Changing of scratching

  Excoriation (scratching marks) was graded on a scale from 0 to 3, with 0 indicating no excoriation, 1 mild, 2 moderate, and 3 severe excoriation.

  4 weeks

• Itching severity

  Itching severity was assessed using an 11-point numeric rating scale (NRS). The NRS-11 evaluates average intensity of pruritus ranging from 0 (no itch) to 10 (worst imaginable itch). Scores were classified into three groups as follows: 0-3 = mild, 4-7 = moderate, and 8-10 = severe.

  4 weeks

Secondary Outcomes (1)

• Adverse events

  4 weeks

Study Arms (2)

Cannabinoid

EXPERIMENTAL

Other: Cannabidiol (CBD)

Triamcinolone cream

ACTIVE COMPARATOR

Drug: Triamcinolone (TAC) 0.1% cream

Interventions

Cannabidiol (CBD) OTHER

5%CBD cream

Cannabinoid

Triamcinolone (TAC) 0.1% cream DRUG

comparator

Triamcinolone cream

Eligibility Criteria

• Age: 25 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All participants must be aged 25 years or older.
• Patients must be diagnosed with eczema, including atopic dermatitis, nummular eczema, lichen simplex chronicus, or prurigo nodularis, with pruritus persisting for more than 6 weeks.
• Patients must be willing to refrain from using other topical products throughout the 4-week study period.
• Patients must provide written informed consent to participate in the study.

You may not qualify if:

• Patients who have taken oral steroids, immunosuppressive drugs, or received phototherapy within the past 3 months.
• Patients with chronic kidney disease, liver cirrhosis, cancer, or thyroid disease.
• Pregnant or breastfeeding women, or women planning to become pregnant.
• Patients who develop erythematous itchy rash in response to an open patch test using cannabis extract products.
• Patients with a known allergy to cannabis-derived products, which may result from other ingredients and/or solvents used in the extraction process.
• Patients with severe or unstable cardio-pulmonary diseases (e.g., angina, peripheral vascular disease, cerebrovascular disease, or arrhythmia), or those at risk of cardiovascular disease.
• Patients with a history of psychosis, current active mood disorder, or anxiety disorder.
• Patients who are addicted to substances, including nicotine, or are heavy alcohol users.
• Patients using other medications, particularly opioids or sedatives such as benzodiazepines.
• Patients taking medications known to potentially interact with cannabis extracts, such as warfarin, fluoroquinolones, or dihydropyridine calcium channel blockers.

Sponsors & Collaborators

• Khon Kaen University: lead

Study Sites (1)

Khon Kaen University

Khon Kaen, Changwat Khon Kaen, 40002, Thailand

Location

MeSH Terms

Conditions

Eczema; Dermatitis, Atopic

Interventions

Cannabidiol; Triamcinolone

Condition Hierarchy (Ancestors)

Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Cannabinoids; Terpenes; Hydrocarbons; Organic Chemicals; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Model Details: Topical cannabidiol versus 0.1% TA cream

Study Record Dates

• First Submitted: May 18, 2025
• First Posted: May 29, 2025
• Study Start: May 1, 2025
• Primary Completion: May 1, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: May 29, 2025

Record last verified: 2025-05

Locations

TH (1)